Home / Pharmaceuticals / Post Traumatic Stress Disorder Therapeutics Market Size, Segmentation, Opportunities, Trends, Growth and Industry Forecast To 2025

Post Traumatic Stress Disorder Therapeutics Market Size, Segmentation, Opportunities, Trends, Growth and Industry Forecast To 2025


Post-Traumatic Stress Disorder (PTSD) is a mental health disorder that one develops after experiencing or witnessing a life threatening event like combat, war, a natural disaster, car accident or sexual assault. The American Psychiatric Association has listed PTSD in the fifth edition of its Diagnostic and Statistical Manual of Mental Disorders (DSM-5), where it defines PTSD as comprised of four clusters of symptoms including intrusive and recurrent memories of the trauma, avoidance of trauma related stimuli, numbing and/or negative changes in mood or cognitions pertaining to the trauma, and changes in reactivity and arousal. PTSD can occur in children too; as they get older their symptoms get similar to that of adults. The diagnosis for PTSD is difficult as patients most of the time avoid opening up about the symptoms, yet one can be diagnosed for PTSD based on the prolongation of symptoms mentioned in DSM-5, wherein the symptoms must last for at least a month.

According to US department of Veterans Affairs 8 million adults have PTSD in a given year in USA. As per NIH the 12 month prevalence of US adult population accounts to 3.5% and among children aged 13-18 years old accounts to 4.0% for PTSD. Women are more likely to develop PTSD than men (10% women; 4% men).

PTSD is associated with co-morbidities such as depressive disorders, anxiety disorders and substance abuse. Data from the National Comorbidity Survey indicate that at least one additional psychiatric disorder is present in 88.3 percent of men and 79.0 percent of women who have a history of PTSD in US. Thus, the treatment for PTSD includes relief of co-morbidities as well.

According to American Psychological Association (APA), treatment for PTSD includes psychotherapy, pharmacotherapy and combination therapy. In case of pharmacotherapy the APA gives a conditional recommendation for Fluoxetine, Paroxetine (Paxil), Sertraline (Zoloft) and Venlafaxine. At present the selective serotonin reuptake inhibitors (SSRI’s) Paroxetine (Paxil) and Sertraline (Zoloft) are the only FDA approved pharmacological treatments for PTSD. The treatment for co-morbidities includes similar medication as for PTSD along with suitable psychotherapy.

There are very few medications in the pipeline for PTSD and here is an increasing growth of PTSD occurrence which could act as a benefit for key players to gauge the market with their innovative medication.

Global Post-Traumatic Stress Disorder- Geographical Analysis:

Around 8 million adults suffer from PTSD in USA, thus North America holds to be a very potential market for PTSD drugs. The rates of traumatic events occurring  in the developing countries is on a rise, the South African Stress and Health Survey  reported a lifetime traumatic event prevalence of 73.8% which is higher than the survey reported in Europe and Japan which ranges from 54-64%, Thus the developing countries may be a potential market for PTSD molecules.

Global Post-Traumatic Stress Disorder- Unmet Needs

Very few molecules in the pipeline for PTSD and no specific standard of care established for PTSD which acts a major drawback for deciding a suitable treatment for PTSD and related co-morbidities. The safety and efficacy concerns of the molecules approved for PTSD also is an issue on the ease of use of such medications.

Global Post-Traumatic Stress Disorder- Market Segmentation

  • Type of treatment
    • Psychotherapy
    • Pharmacotherapy
      • Selective serotonin reuptake inhibitors
      • Other Antidepressants
  • Etiology
    • Combat/War
    • Car Accidents
    • Natural Disaster
    • Sexual assault
  • Geography
    • North America
      • US
      • Canada
    • Europe
      • UK
      • Germany
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • Rest of APAC
    • Latin America           
    • Middle East and Africa

Key Players Identified for Post-Traumatic Stress Disorder (PTSD) Treatment but are Not Limited to:

The key players in the market are GlaxoSmithKline, AstraZeneca plc., UCB Pharma, Janssen, Otsuka Pharmaceuticals, Bionomics limited, Novartis AG, Pfizer,Inc., Eli Lilly & Company, Marinus Pharmaceuticals, Takeda, Forest Laboratories, Merck Sharp & Dohme Corp, Biotie Therapies Inc., Tonix Pharmaceuticals, Humanetics Corp and Azevan Pharmaceuticals.

This report offers:

  • An overview of the global markets for Post-Traumatic Stress Disorder (PTSD) treatment
  • Market trends assessment for the period 2015-2025, with historical information for 2015, and projections through 2025, with respective CAGRS during 2017-2025
  • Qualitative assessment tools such as market drivers, challenges and opportunities
  • Market competition scrutiny tools such as market share analysis, fractal map assessment, Porter’s Five Forces model
  • Focus on each level of market segmentation based on product approvals, launch, and current and anticipated market dynamics.
  • A general overview of the industry structure
  • Company profiles highlighting key information about the major players operating in the Post-Traumatic Stress Disorder treatment market
Choose License Type
Connect With Us
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients